ArticleDiscover oncology2026
Acute promyelocytic leukemia with a unique genetic signature: a case report and management.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Acute Promyelocytic Leukemia (APL) is a specific type of Acute Myeloid Leukemia (AML) characterized by the chromosomal abnormality t(15;17)(q22;q21), leading to the formation of the PML-RARα fusion gene. This fusion gene can be detected using Reverse Transcription Polymerase Chain Reaction (RT-PCR) or Fluorescence In Situ Hybridization (FISH), and these methods are the gold standards for diagnosing APL. This report describes a 59-year-old male patient who presented with tooth pain, gum bleeding, pancytopenia, and abnormal coagulation function. Through clinical manifestations, immunophenotyping, cytogenetics, and bone marrow chromosome karyotype analysis, the patient was found to have a rare variant karyotypeof46,XY,t(15;17;21)(q24;q21;q21)[14]/46,idem,add(22)(p11.2)[3]/46,XY[3],involving mutations in three types of genes: PML::RARA fusion gene, FLT3-TKD, and DNMT3A, which are closely associated with APL. Following dual-induction chemotherapy with all-trans retinoic acid (ATRA) and compound Huangdai tablets, the patient’s vital signs stabilized, the karyotype normalized, complete remission of the bone marrow was achieved, and the condition was effectively controlled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.